276?1253660878
New Treatments in Development User Group
Understanding NMDA Receptor Modulates
About This Group:

This group is to discuss new treatments in development to have a better understanding of the future of recovery.

Founded by ILADVOCATE on September 22, 2009
41 members
Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

Understanding NMDA Receptor Modulates

The NMDA receptor modulates are a class of antipsychotic in Phase II FDA study. Glycine is one of these compounds. I am on glycine under strict clinical supervision because I was unable to tolerate all known antipsychotics and have advanced tardive dyskinesia. For more information on glycine google "Dr. Javitt, glycine". Glycine is not FDA approved so this discussion is for informational purposes only. Unlike known antipsychotics, the NMDA receptor modulates do not cause tardive dyskinesia or diabetes and appear to promote a fuller recovery but all the study results are of course tentative but the results are quite promising.
Related Discussions
2 Comments
Blank
Avatar_m_tn
I'm hoping this gets pushed through.  I'd love to take a medicine that doesn't have the chance of causing serious side effects like the diabetes or tardive dyskinesia or you know things like significant weight gain and extreme sedation and all that bullsh*t people on antipsychotics have to put up with.
Blank
585414_tn?1288944902
Right now there are many NMDA receptor modulates in ongoing Phase II FDA studies. Glycine itself since it is a compound that is hard to take (because it requires 20-40 grams of powdered format that must be mixed with water, in studies some people discontinued it because of nausea or vomiting relating to swallowing this amount) and also in the standard studies it must be taken with a conventional antipsychotic. However, there are other NMDA receptor modulates that are specifically targeted to the receptors that are in Phase II FDA study and will be available in standard pill format like all medications and will be able to take as primary (stand alone antipsychotics). Many companies are researching them but Eli Lilly has two promising ones. Here is a standard article on one of them:
http://www.nytimes.com/2007/09/03/business/03drug.html?_r=1
Its not just the side effect profile. In studies they showed an increased beneficial effect on cognitive and negative symptoms, including glycine itself. I am the first to show a further beneficial effect on positive symptoms but as the studies progress they will understand more about this class of antipsychotics in general.
Blank
Recent Activity
675718_tn?1321008971
Blank
drifter0213 commented on my love
Jul 10
495284_tn?1333897642
Blank
dominosarah commented on my love
Jul 09
271792_tn?1334983257
Blank
IBKleen commented on my love
Jul 09
MedHelp Health Answers